

General

Guideline Title

Screening tests of unproven benefit. In: Guidelines for preventive activities in general practice, 8th edition.

Bibliographic Source(s)

Screening tests of unproven benefit. In: Guidelines for preventive activities in general practice, 8th edition. East Melbourne (Australia): Royal Australian College of General Practitioners; 2012. p. 85-6.

Guideline Status

This is the current release of the guideline.

Recommendations

Major Recommendations

The following are not recommended as screening tests in low-risk general practice populations. These tests may have value as diagnostic tests or as tests to monitor disease progression.

Screening Tests of Unproven Benefit

Screening Tests Not Recommended in Low-risk General Practice Populations

Screening Test	Condition	Reason Not to Use	References for Further Reading
Genetic profiling	Genetic disorders	Limited evidence on the balance of benefits and harms, ethical issues and uncertain utility.	Udesky, 2010; Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, 2010
<i>Vascular</i>			
Cardiac computerised tomography (CT)	Coronary heart disease (CHD)	No randomised controlled trial (RCT) evidence. RCTs of therapy show no effect on coronary artery progression. May be of benefit in those at intermediate risk of CHD.	Taylor et al., 2010; McEvoy et al., 2010; US Preventive Services Task Force (USPSTF), "Using," 2009
Serum homocysteine	CHD	Value as a risk factor for CHD is uncertain and published RCTs show no evidence of benefit by	USPSTF, "Using," 2009; Loland et al., 2010; Potter, Lenzo, & Eikelboom, 2009

Screening Test	Condition	Reason Not to Use	References for Further Reading
Exercise electrocardiograph (ECG)	CHD	Lowering levels. Low yield and high false positive rate given low prevalence in asymptomatic population.	USPSTF, "Using," 2009; Lim et al., 2011
High sensitivity C-reactive protein (CRP)	Cardiovascular disease (CVD)	Some evidence of benefit (i.e., reduction in CRP linked with reduction in major CVD events in one study, but not currently recommended as a screening test for CVD).	USPSTF, "Using," 2009; Lim et al., 2011; Helfand et al., 2009; Genest et al., 2009; Buckley et al., 2009; Kones, 2009
Ankle:brachial index (ABI)	Peripheral vascular disease	Longitudinal studies showing increased risk of clinical CVD if low ABI, but there is variable reliability and low sensitivity of assessment and no published RCT evidence showing benefit of screening.	Helfand et al., 2009; Grondal et al., 2010; Ankle Brachial Index Collaboration et al., 2008
<i>Cancer</i>			
Magnetic resonance imaging (MRI)	Breast cancer	Ongoing surveillance strategies for women at high risk of breast cancer may include imaging with MRI. A Medicare rebate is available for MRI scans for asymptomatic women under 50 years at high risk of breast cancer.	National Breast and Ovarian Cancer Centre (NBOCC), "Early detection," 2009; NBOCC, 2010; National Breast Cancer Centre (NBCC), 2006; USPSTF, "Screening for breast cancer," 2009; Australian Department of Health and Ageing, 2012
Cancer antigen (CA)125/transvaginal ultrasound	Ovarian cancer	There is no evidence to support the use of any test – including pelvic examination, CA125, or other biomarkers, ultrasound (including transvaginal ultrasound), or combination of tests – for routine population-based screening for ovarian cancer. CA125 is limited by poor sensitivity in early-stage disease and low specificity. The specificity of transvaginal ultrasound is low. The low prevalence of ovarian cancer means that even screening tests that have very high sensitivity and specificity have a low positive predictive value for disease detection.	Schorge et al., 2010; NBOCC, "Population screening," 2009
Virtual colonoscopy/CT colonography	Colorectal cancer (CRC)	Good sensitivity for lesions larger than 10 mm, but no evidence of reduction of CRC incidence or mortality. Not currently recommended.	Zauber et al., 2009; Philip, Lubner, & Harms, 2011; Weizman & Nguyen, 2010; Pox & Schmiegell, 2010; Laghi et al., 2010; Lieberman, 2009
Whole body CT or MRI	Cancer	Whole body imaging has not been shown to improve quality of life and/or decrease mortality. It is associated with additional radiation exposure and a high number of false positive results. There are no RCTs of whole body imaging to detect cancer or CVD.	Weltermann, Hermann, & Gesenhues, 2010; Canadian Health Services Research Foundation, 2010; Ladd, 2009; Fayngersh & Passero, 2009; Schoder & Gonen, 2007; Anderiesz et al., 2004
<i>Lung Disease</i>			
Spirometry	Chronic obstructive pulmonary disease (COPD)	Assessment is unreliable and screening for COPD using spirometry has no net benefit.	O'Reilly & Rudolf, 2011; COPD Guidelines Committee, 2011; "Screening for chronic," 2009; O'Donnell et al., 2008

<i>Endocrine</i> Screening Test Thyroid function tests	Condition Thyroid dysfunction	Reason Not to Use Despite the relatively high incidence of subclinical hypothyroidism in older women (up to 17%), there is a lack of convincing data from controlled trials that early treatment reduces lipid levels, symptoms or the risk for CVD in patients with mild thyroid dysfunction detected by screening.	References for Further Reading Gopinath et al., 2010; Ochs et al., 2008; Empson et al., 2007; Helfand, 2004
<i>Chronic Disease Prevention</i>			
Vitamin D	Vitamin D deficiency	High prevalence, variability in assessment and lack of rigorous evidence of benefit of screening.	Bjelakovic et al., 2011; Chung et al., 2010; Hanley et al., 2010; Holick et al., 2011; Wang et al., 2010
<i>Infection</i>			
Midstream urine (MSU) culture	Asymptomatic bacteriuria (elderly)	Identifying and treating non-pregnant adults with asymptomatic bacteriuria does not improve outcomes and may increase antibiotic resistance.	Lin, Fajardo & USPSTF, 2008

Screening Tests of Indeterminate Value

Screening Test	Condition	Reason Not to Use	References
<i>Women</i>			
Vitamin D	Pregnancy	Moderate prevalence and associated morbidity, but no randomised controlled trial (RCT) evidence of benefit. There is debate about what is an adequate level of vitamin D. High-risk groups for vitamin D deficiency may benefit from screening and supplementation.	Ebeling, 2011; Dror & Allen, 2010; Lichtenstein, 2009; Holmes, et al., 2009
<i>Vascular</i>			
Ultrasound	Abdominal aneurysm	USPSTF recommend screening, but low yield as declining incidence and ethical issues of screening only one subgroup (male smokers), and cost-effectiveness not clear.	Aggarwal et al., 2011; Ferket et al., 2012; "Screening," 2005
B-type natriuretic peptide (BNP)	Congestive cardiac failure	The evidence for screening for heart failure using BNP is mixed despite its sensitivity and prognostic significance. It may be useful in excluding the condition in suspected heart failure.	Felker et al., 2009; Krum et al., 2011; National Institute for Health and Clinical Excellence, 2010; Porapakham et al., 2010
<i>Cancer</i>			
Chest computerised tomography (CT)	Lung cancer	Good sensitivity but poor specificity; one RCT underway in smokers has preliminary results showing a 20% reduction in mortality in the CT arm. Low-dose CT screening may benefit individuals at an increased risk for lung cancer, but uncertainty exists about the potential harms of screening and the generalisability of results. Approximately 20% of individuals in each round of screening had positive results requiring some degree of follow-up, while approximately 1% had lung cancer.	Mulshine & van Klaveren, 2011; Baldwin, 2011; Bach et al., 2012
Positron emission tomography (PET) – CT	Lung cancer	Good sensitivity and specificity, but no RCT results.	Baldwin, 2011

(or PET/CT scan) Screening Test	Condition	Reason Not to Use	References
<i>Elderly</i>			
Visual acuity	Visual impairment	No benefits of screening, even though impaired visual acuity is common and effective treatments are available.	Smeeth & Iliffe, 2006; Chou, Dana, & Bougatsos, 2009

Clinical Algorithm(s)

None provided

Scope

Disease/Condition(s)

- Genetic disorders
- Coronary heart disease
- Cardiovascular disease
- Peripheral vascular disease
- Abdominal aneurysm
- Congestive cardiac failure
- Breast cancer
- Ovarian cancer
- Colorectal cancer
- Lung cancer
- Chronic obstructive pulmonary disease
- Thyroid dysfunction
- Vitamin D deficiency, including deficiency in pregnancy
- Asymptomatic bacteriuria
- Visual impairment

Guideline Category

Prevention

Screening

Clinical Specialty

Cardiology

Endocrinology

Family Practice

Geriatrics

Medical Genetics

Obstetrics and Gynecology

Oncology

Ophthalmology

Optometry

Preventive Medicine

Pulmonary Medicine

Intended Users

Advanced Practice Nurses

Health Care Providers

Nurses

Physician Assistants

Physicians

Public Health Departments

Guideline Objective(s)

- To provide a comprehensive and concise set of recommendations for patients in general practice with additional information about tailoring risk and need
- To provide the evidence base for which primary healthcare resources can be used efficiently and effectively while providing a rational basis to ensure the best use of time and resources in general practice

Target Population

Low-risk general practice populations in Australia, including pregnant women and the elderly

Interventions and Practices Considered

1. Genetic profiling for genetic disorders
2. Cardiac computed tomography (CT) for coronary heart disease (CHD)
3. Serum homocysteine measurement for CHD
4. Exercise electrocardiography (ECG) for CHD
5. High-sensitivity C-reactive protein (CRP) for cardiovascular disease (CVD)
6. Ankle:brachial index (ABI) for peripheral vascular disease
7. Magnetic resonance imaging (MRI) for breast cancer
8. Cancer antigen (CA) 125 and transvaginal ultrasound for ovarian cancer
9. Virtual colonoscopy/CT colonography for colorectal cancer
10. Whole body CT or MRI for cancer
11. Chest CT for lung cancer
12. Positron emission tomography (PET)-CT for lung cancer
13. Spirometry for chronic obstructive pulmonary disease (COPD)
14. Thyroid function tests for thyroid dysfunction
15. Screening for vitamin D deficiency
16. Midstream urine culture for asymptomatic bacteriuria in the elderly
17. Screening for visual impairment in the elderly
18. Ultrasound for abdominal aneurysm
19. B-type natriuretic peptide (BNP) for congestive cardiac failure

Note: None of the tests are recommended as screening tests in low-risk general practice populations. These tests may have value as diagnostic tests or as tests to monitor disease progression.

Major Outcomes Considered

- Sensitivity and specificity of screening tests
- Prognostic value and diagnostic yield of screening tests
- False-positive and false-negative results
- Benefits and harms of screening tests
- Quality of life
- Mortality

Methodology

Methods Used to Collect/Select the Evidence

Hand-searches of Published Literature (Primary Sources)

Hand-searches of Published Literature (Secondary Sources)

Searches of Electronic Databases

Description of Methods Used to Collect/Select the Evidence

Sources of Recommendations

The recommendations in these guidelines are based on current, evidence-based guidelines for preventive activities. The Taskforce focused on those most relevant to Australian general practice. Usually this means that the recommendations are based on Australian guidelines such as those endorsed by the National Health and Medical Research Council (NHMRC).

In cases where these are not available or recent, other Australian sources have been used, such as guidelines from the Heart Foundation, Canadian or United States preventive guidelines, or the results of systematic reviews. References to support these recommendations are listed. However, particular references may relate to only part of the recommendation (e.g., only relating to one of the high-risk groups listed) and other references in the section may have been considered in formulating the overall recommendation.

Number of Source Documents

Not stated

Methods Used to Assess the Quality and Strength of the Evidence

Weighting According to a Rating Scheme (Scheme Given)

Rating Scheme for the Strength of the Evidence

Levels of Evidence

Level	Explanation
I	Evidence obtained from a systematic review of level II studies
II	Evidence obtained from a randomised controlled trial (RCT)

Level	Explanation
III-1	Evidence obtained from a pseudo-randomised controlled trial (i.e., alternate allocation or some other method)
III-2	Evidence obtained from a comparative study with concurrent controls: <ul style="list-style-type: none"> • Non-randomised, experimental trial • Cohort study • Case-control study • Interrupted time series with a control group
III-3	Evidence obtained from a comparative study without concurrent controls: <ul style="list-style-type: none"> • Historical control study • Two or more single arm study • Interrupted time series without a parallel control group
IV	Case series with either post-test or pre-test/post-test outcomes
Practice Point	Opinions of respected authorities, based on clinical experience, descriptive studies or reports of expert committees

Methods Used to Analyze the Evidence

Review of Published Meta-Analyses

Systematic Review

Description of the Methods Used to Analyze the Evidence

Not stated

Methods Used to Formulate the Recommendations

Expert Consensus

Description of Methods Used to Formulate the Recommendations

These *Guidelines for preventive activities in general practice*, 8th edition, have been developed by a taskforce of general practitioners (GPs) and experts to ensure that the content is the most valuable and useful for GPs and their teams. The guidelines provide an easy, practical and succinct resource. The content broadly conforms to the highest evidence-based standards according to the principles underlying the Appraisal of Guidelines Research and Evaluation.

The dimensions addressed are:

- Scope and purpose
- Clarity of presentation
- Rigour of development
- Stakeholder involvement
- Applicability
- Editorial independence

The Red Book maintains developmental rigour, editorial independence, relevance and applicability to general practice.

Screening Principles

The World Health Organization (WHO) has produced guidelines for the effectiveness of screening programs. The Taskforce has kept these and

the United Kingdom National Health Services' guidelines in mind in the development of recommendations about screening and preventive care.

Rating Scheme for the Strength of the Recommendations

Grades of Recommendations

Grade	Explanation
A	Body of evidence can be trusted to guide practice
B	Body of evidence can be trusted to guide practice in most situations
C	Body of evidence provides some support for recommendation(s) but care should be taken in its application
D	Body of evidence is weak and recommendation must be applied with caution

Cost Analysis

A formal cost analysis was not performed and published cost analyses were not reviewed.

Method of Guideline Validation

Peer Review

Description of Method of Guideline Validation

Not stated

Evidence Supporting the Recommendations

References Supporting the Recommendations

Aggarwal S, Qamar A, Sharma V, Sharma A. Abdominal aortic aneurysm: A comprehensive review. *Exp Clin Cardiol*. 2011 Spring;16(1):11-5. [PubMed](#)

Anderiesz C, Elwood JM, McAvoy BR, Kenny LM. Whole-body computed tomography screening: looking for trouble. *Med J Aust*. 2004 Sep 20;181(6):295-6. [PubMed](#)

Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, Folsom AR, Hirsch AT, Dramaix M, deBacker G, Wautrecht JC, Kornitzer M, Newman AB, Cushman M, Sutton-Tyrrell K, Fowkes FG, Lee AJ, Price JF, d'Agostino RB, Murabito JM, Norman PE, Jamrozik K, Curb JD, Masaki KH, Rodriguez BL, Dekker JM, Bouter LM, Heine RJ, Nijpels G, Stehouwer CD, Ferrucci L, McDermott MM, Stoffers HE, Hooi JD, Knottnerus JA, Ogren M, Hedblad B, Wittman JC, Breteler MM, Hunink MG, Hofman A, Criqui MH, Langer RD, Fronck A, Hiatt WR, Hamman R, Resnick HE, Guralnik J, McDermott MM. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. *JAMA*. 2008 Jul 9;300(2):197-208. [48 references] [PubMed](#)

Australian Department of Health and Ageing. MBS Online - medicare benefits schedule. [internet]. [accessed 2012 Jun 01].

Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, Byers T, Colditz GA, Gould MK, Jett JR, Sabichi AL, Smith-Bindman R, Wood DE, Qaseem A, Detterbeck FC. Benefits and harms of CT screening for lung cancer: a systematic review. *JAMA*. 2012 Jun 13;307(22):2418-29. [PubMed](#)

Baldwin DR. Imaging in lung cancer: recent advances in PET-CT and screening. *Thorax*. 2011 Apr;66(4):275-7. [PubMed](#)

Bjelakovic G, Glud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG, Bjelakovic M, Glud C. Vitamin D supplementation for prevention of mortality in adults. *Cochrane Database Syst Rev*. 2011;(7):CD007470. [PubMed](#)

Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2009 Oct 6;151(7):483-95. [98 references] [PubMed](#)

Canadian Health Services Research Foundation. Myth: whole-body screening is an effective way to detect hidden cancers. *J Health Serv Res Policy*. 2010 Apr;15(2):118-9. [PubMed](#)

Chou R, Dana T, Bougatsos C. Screening older adults for impaired visual acuity: a review of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2009 Jul 7;151(1):44-58, W11-20. [91 references] [PubMed](#)

Chung M, Balk EM, Ip S, Lee J, Terasawa T, Raman G, Trikalinos T, Lichtenstein AH, Lau J. Systematic review to support the development of nutrient reference intake values: challenges and solutions. *Am J Clin Nutr*. 2010 Aug;92(2):273-6. [PubMed](#)

COPD Guidelines Committee. The COPD-X: Australian and New Zealand Guidelines for the management of chronic obstructive pulmonary disease. Canberra: Australian Lung Foundation and the Thoracic Society of Australia and New Zealand; 2011.

Dror DK, Allen LH. Vitamin D inadequacy in pregnancy: biology, outcomes, and interventions. *Nutr Rev*. 2010 Aug;68(8):465-77. [127 references] [PubMed](#)

Ebeling PR. Routine screening for vitamin D deficiency in early pregnancy: past its due date. *Med J Aust*. 2011 Apr 4;194(7):332-3. [PubMed](#)

Empson M, Flood V, Ma G, Eastman CJ, Mitchell P. Prevalence of thyroid disease in an older Australian population. *Intern Med J*. 2007 Jul;37(7):448-55. [PubMed](#)

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genomic profiling to assess cardiovascular risk to improve cardiovascular health. *Genet Med*. 2010 Dec;12(12):839-43. [18 references] [PubMed](#)

Fayngersh V, Passero M. Estimating radiation risk from computed tomography scanning. *Lung*. 2009 May-Jun;187(3):143-8. [51 references] [PubMed](#)

Felker GM, Hasselblad V, Hernandez AF, O'Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. *Am Heart J*. 2009 Sep;158(3):422-30. [PubMed](#)

Ferket BS, Grootenboer N, Colkesen EB, Visser JJ, van Sambeek MR, Spronk S, Steyerberg EW, Hunink MG. Systematic review of

guidelines on abdominal aortic aneurysm screening. *J Vasc Surg.* 2012 May;55(5):1296-1304. [PubMed](#)

Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, Couture P, Dufour R, Fodor G, Francis GA, Grover S, Gupta M, Hegele RA, Lau DC, Leiter L, Lewis GF, Lonn E, Mancini GB, Ng D, Pearson GJ, Sniderman A, Stone JA, Ur E. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. *Can J Cardiol.* 2009 Oct;25(10):567-79. [79 references] [PubMed](#)

Gopinath B, Wang JJ, Kifley A, Wall JR, Eastman CJ, Leeder SR, Mitchell P. Five-year incidence and progression of thyroid dysfunction in an older population. *Intern Med J.* 2010 Sep;40(9):642-9. [PubMed](#)

Grondal N, Sogaard R, Heneberg EW, Lindholt JS. The Viborg Vascular (VIVA) screening trial of 65-74 year old men in the central region of Denmark: study protocol. *Trials.* 2010;11:67. [PubMed](#)

Hanley DA, Cranney A, Jones G, Whiting SJ, Leslie WD, Guidelines Committee of the Scientific Advisory Council of Osteoporosis Canada. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada (summary). *CMAJ.* 2010 Sep 7;182(12):1315-9. [51 references] [PubMed](#)

Helfand M, Buckley DI, Freeman M, Fu R, Rogers K, Flening C, Humphrey LL. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2009 Oct 6;151(7):496-507. [212 references] [PubMed](#)

Helfand M. Screening for subclinical thyroid dysfunction in nonpregnant adults: a summary of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2004 Jan 20;140(2):128-41. [87 references] [PubMed](#)

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2011 Jul;96(7):1911-30. [143 references] [PubMed](#)

Holmes VA, Barnes MS, Alexander HD, McFaul P, Wallace JM. Vitamin D deficiency and insufficiency in pregnant women: a longitudinal study. *Br J Nutr.* 2009 Sep;102(6):876-81. [PubMed](#)

Kones R. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease. *Ther Adv Cardiovasc Dis.* 2009 Aug;3(4):309-15. [41 references] [PubMed](#)

Krum H, Jelinek MV, Stewart S, Sindone A, Atherton JJ, National Heart Foundation of Australia, Cardiac Society of Australia and New Zealand. 2011 update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006. *Med J Aust.* 2011 Apr 18;194(8):405-9. [PubMed](#)

Ladd SC. Whole-body MRI as a screening tool. *Eur J Radiol.* 2009 Jun;70(3):452-62. [75 references] [PubMed](#)

Laghi A, Iafrate F, Rengo M, Hassan C. Colorectal cancer screening: the role of CT colonography. *World J Gastroenterol.* 2010 Aug 28;16(32):3987-94. [PubMed](#)

Lichtenstein AH. Nutrient supplements and cardiovascular disease: a heartbreaking story. *J Lipid Res.* 2009 Apr;50(Suppl):S429-33. [69 references] [PubMed](#)

Lieberman DA. Clinical practice. Screening for colorectal cancer. *N Engl J Med*. 2009 Sep 17;361(12):1179-87. [55 references] [PubMed](#)

Lim LS, Haq N, Mahmood S, Hoeksema L, ACPM Prevention Practice Committee, American College of Preventive Medicine. Atherosclerotic cardiovascular disease screening in adults: American College of Preventive Medicine position statement on preventive practice. *Am J Prev Med*. 2011 Mar;40(3):381.e1-10. [55 references] [PubMed](#)

Lin K, Fajardo K, U.S. Preventive Services Task Force. Screening for asymptomatic bacteriuria in adults: evidence for the U.S. Preventive Services Task Force reaffirmation recommendation statement. *Ann Intern Med*. 2008 Jul 1;149(1):W20-4. [9 references] [PubMed](#)

Loland KH, Bleie O, Blix AJ, Strand E, Ueland PM, Refsum H, Ebbing M, Nordrehaug JE, Nygard O. Effect of homocysteine-lowering B vitamin treatment on angiographic progression of coronary artery disease: a Western Norway B Vitamin Intervention Trial (WENBIT) substudy. *Am J Cardiol*. 2010 Jun 1;105(11):1577-84. [PubMed](#)

McEvoy JW, Blaha MJ, Defilippis AP, Budoff MJ, Nasir K, Blumenthal RS, Jones SR. Coronary artery calcium progression: an important clinical measurement? A review of published reports. *J Am Coll Cardiol*. 2010 Nov 9;56(20):1613-22. [PubMed](#)

Mulshine JL, van Klaveren RJ. Lung cancer screening: what is the benefit and what do we do about it. *Lung Cancer*. 2011 Mar;71(3):247-8. [PubMed](#)

National Breast and Ovarian Cancer Centre (NBOCC). Advice about familial aspects of breast and epithelial ovarian cancer: a guide for health professionals. Sydney: National Breast and Ovarian Cancer Centre (NBOCC); 2010.

National Breast and Ovarian Cancer Centre. Early detection of breast cancer - NBOCC position statement. [internet]. Sydney: National Breast and Ovarian Cancer Centre (NBOCC); 2009 [accessed 2012 May 01].

National Breast and Ovarian Cancer Centre. Population screening and early detection of ovarian cancer in asymptomatic women - NBOCC position statement. [internet]. 2009 [accessed 2012 May 01].

National Breast Cancer Centre (NBCC). Magnetic resonance imaging for the early detection of breast cancer in women at high risk: a systematic review of evidence. Sydney: National Breast Cancer Centre (NBCC); 2006.

National Institute for Health and Clinical Excellence (NICE). Chronic heart failure. National clinical guideline for diagnosis and management in primary and secondary care. London: National Institute for Health and Clinical Excellence (NICE); 2010.

Ochs N, Auer R, Bauer DC, Nanchen D, Gussekloo J, Cornuz J, Rodondi N. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. *Ann Intern Med*. 2008 Jun 3;148(11):832-45. [PubMed](#)

O'Donnell DE, Hernandez P, Kaplan A, Aaron S, Bourbeau J, Marciniuk D, Balter M, Ford G, Gervais A, Lacasse Y, Maltais F, Road J, Rocker G, Sin D, Sinuff T, Voduc N. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. *Can Respir J*. 2008 Jan-Feb;15(Suppl A):1A-8A. [PubMed](#)

O'Reilly J, Rudolf M. What's nice about the new NICE guideline. *Thorax*. 2011 Feb;66(2):93-6. [PubMed](#)

Philip AK, Lubner MG, Harms B. Computed tomographic colonography. *Surg Clin North Am*. 2011 Feb;91(1):127-39. [PubMed](#)

Porapakkhram P, Porapakkhram P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. *Arch Intern Med*. 2010 Mar 22;170(6):507-14. [PubMed](#)

Potter K, Lenzo N, Eikelboom JW, Arnolda LF, Beer C, Hankey GJ. Effect of long-term homocysteine reduction with B vitamins on arterial wall inflammation assessed by fluorodeoxyglucose positron emission tomography: a randomised double-blind, placebo-controlled trial. *Cerebrovasc Dis*. 2009;27(3):259-65. [PubMed](#)

Pox CP, Schmieg W. Role of CT colonography in colorectal cancer screening: risks and benefits. *Gut*. 2010 May;59(5):692-700. [PubMed](#)

Schoder H, Gonen M. Screening for cancer with PET and PET/CT: potential and limitations. *J Nucl Med*. 2007 Jan;48(Suppl 1):4S-18S. [114 references] [PubMed](#)

Schorge JO, Modesitt SC, Coleman RL, Cohn DE, Kauff ND, Duska LR, Herzog TJ. SGO white paper on ovarian Cancer: Etiology, screening and surveillance. *Gynecol Oncol*. 2010 Oct;119(1):7-18. [116 references] [PubMed](#)

Screening for abdominal aortic aneurysm: recommendation statement. *Ann Intern Med*. 2005 Feb 1;142(3):198-202. [PubMed](#)

Screening for chronic obstructive pulmonary disease using spirometry: recommendation statement. *Am Fam Physician*. 2009 Oct 15;80(8):853. [1 reference] [PubMed](#)

Smeeth L, Iliffe S. Community screening for visual impairment in the elderly. *Cochrane Database Syst Rev*. 2006;(3):CD001054. [37 references] [PubMed](#)

Taylor AJ, Cerqueira M, Hodgson JM, Mark D, Min J, O'Gara P, Rubin GD, American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society of Cardiovascular Computed Tomography, American College of Radiology, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, North American Society for Cardiovascular Imaging, Society for Cardiovascular Angiography and Interventions, Society for Cardiovascular Magnetic Resonance, Kramer CM, Berman D, Brown A, Chaudhry FA, Cury RC, Desai MY, Einstein AJ, Gomes AS, Harrington R, Hoffmann U, Khare R, Lesser J, McGann C, Rosenberg A, Schwartz R, Shelton M, Smetana GW, Smith SC Jr. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography. A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force [trunc]. *J Am Coll Cardiol*. 2010 Nov 23;56(22):1864-94. [PubMed](#)

U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2009 Nov 17;151(10):716-26. [PubMed](#)

U.S. Preventive Services Task Force. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2009 Oct 6;151(7):474-82. [40 references] [PubMed](#)

Udesky L. The ethics of direct-to-consumer genetic testing. *Lancet*. 2010 Oct 23;376(9750):1377-8. [PubMed](#)

Wang L, Manson JE, Song Y, Sesso HD. Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. *Ann Intern Med*. 2010 Mar 2;152(5):315-23. [67 references] [PubMed](#)

Weizman AV, Nguyen GC. Colon cancer screening in 2010: an up-date. *Minerva Gastroenterol Dietol*. 2010 Jun;56(2):181-8. [62 references] [PubMed](#)

Weltermann B, Hermann M, Gesenhues S. [Diagnostic screening for cancer and coronary heart disease with radiological and nuclear imaging techniques: early diagnosis at any price?]. *Dtsch Med Wochenschr*. 2010 Apr;135(16):813-8. [23 references] [PubMed](#)

Zauber AG, Lansdorf-Vogelaar I, Knudsen AB, Wilschut J. Evaluating test strategies for colorectal cancer screening - age to begin, age to stop, and timing of screening intervals: a decision analysis of colorectal cancer screening for the US Preventive Task Force [trunc]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2009.

Type of Evidence Supporting the Recommendations

The type of evidence supporting the recommendations is not specifically stated.

Benefits/Harms of Implementing the Guideline Recommendations

Potential Benefits

Appropriate use of screening and diagnostic tests in the low-risk general practice population

Potential Harms

Potential harms of specific tests are provided in the "Major Recommendations" field.

Qualifying Statements

Qualifying Statements

- The information set out in this publication is current at the date of first publication and is intended for use as a guide of a general nature only and may or may not be relevant to particular patients or circumstances. Nor is this publication exhaustive of the subject matter. Persons implementing any recommendations contained in this publication must exercise their own independent skill or judgement or seek appropriate professional advice relevant to their own particular circumstances when so doing. Compliance with any recommendations cannot of itself guarantee discharge of the duty of care owed to patients and others coming into contact with the health professional and the premises from which the health professional operates.
- Whilst the text is directed to health professionals possessing appropriate qualifications and skills in ascertaining and discharging their professional (including legal) duties, it is not to be regarded as clinical advice and, in particular, is no substitute for a full examination and consideration of medical history in reaching a diagnosis and treatment based on accepted clinical practices.
- Accordingly, the Royal Australian College of General Practitioners and its employees and agents shall have no liability (including without limitation liability by reason of negligence) to any users of the information contained in this publication for any loss or damage (consequential or otherwise), cost or expense incurred or arising by reason of any person using or relying on the information contained in this publication and whether caused by reason of any error, negligent act, omission or misrepresentation in the information.
- These guidelines have not included detailed information on the management of risk factors or early disease (e.g., what medications to use in treating hypertension). Similarly, they have not made recommendations about tertiary prevention (preventing complications in those with established disease). Also, information about prevention of infectious diseases has been limited largely to immunisation and some sexually transmitted infections (STIs).

Implementation of the Guideline

Description of Implementation Strategy

For preventive care to be most effective, it needs to be planned, implemented and evaluated. Planning and engaging in preventive health is increasingly expected by patients. The Royal Australian College of General Practitioners (RACGP) thus provides the Red Book and *National guide to inform evidence-based guidelines*, and the Green Book (see the "Availability of Companion Documents" field) to assist in development of programs of implementation. The RACGP is planning to introduce a small set of voluntary clinical indicators to enable practices to monitor their preventive activities.

Implementation Tools

Resources

For information about availability, see the *Availability of Companion Documents* and *Patient Resources* fields below.

Institute of Medicine (IOM) National Healthcare Quality Report Categories

IOM Care Need

Staying Healthy

IOM Domain

Effectiveness

Patient-centeredness

Identifying Information and Availability

Bibliographic Source(s)

Screening tests of unproven benefit. In: Guidelines for preventive activities in general practice, 8th edition. East Melbourne (Australia): Royal Australian College of General Practitioners; 2012. p. 85-6.

Adaptation

This guideline has been partially adapted from Australian, Canadian, United Kingdom, and/or United States preventive guidelines.

Date Released

2012

Guideline Developer(s)

Source(s) of Funding

Royal Australian College of General Practitioners

Guideline Committee

Red Book Taskforce

Composition of Group That Authored the Guideline

Taskforce Members: Dr Evan Ackermann (*Chair*), Chair, National Standing Committee for Quality Care, RACGP; Professor Mark Harris, Centre for Primary Health Care and Equity, University of New South Wales, National Standing Committee for Quality Care, RACGP; Dr Karyn Alexander, General practitioner, Victoria; Dr Meredith Arcus, General practitioner, Western Australia; Linda Bailey, Project Manager, Red Book Taskforce; Dr John Bennett, Chair, National Standing Committee for e-Health, RACGP; Associate Professor Pauline Chiarelli, School of Health Sciences, University of Newcastle, New South Wales; Professor Chris Del Mar, Faculty of Health Sciences and Medicine, Bond University, Queensland; Professor Jon Emery, School of Primary, Aboriginal and Rural Health Care, The University of Western Australia, National Standing Committee for Research, RACGP; Dr Ben Ewald, School of Medicine and Public Health, University of Newcastle, New South Wales; Dr Dan Ewald, General practitioner, New South Wales, Adjunct Associate Professor, Northern Rivers University Centre for Rural Health, and Clinical Advisor North Coast NSW Medicare Local; Professor Michael Fasher, Adjunct Associate Professor, University of Sydney, and Conjoint Associate Professor, University of Western Sydney, New South Wales; Dr John Furler, Department of General Practice, The University of Melbourne, Victoria; Dr Faline Howes, General practitioner, Tasmania; Dr Caroline Johnson, Department of General Practice, The University of Melbourne, Victoria, National Standing Committee for Quality Care, RACGP; Dr Beres Joyner, General practitioner, Queensland; Associate Professor John Litt, Department of General Practice, Flinders University, South Australia, Deputy Chair, National Standing Committee for Quality Care, RACGP; Professor Danielle Mazza, Department of General Practice, School of Primary Care, Monash University, Victoria, National Standing Committee for Quality Care, RACGP; Professor Dimity Pond, School of Medicine and Public Health, University of Newcastle, New South Wales; Associate Professor Lena Sanci, Department of General Practice, The University of Melbourne, Victoria; Associate Professor Jane Smith, Faculty of Health Sciences and Medicine, Bond University, Queensland; Dr Tania Wirzenberg, Deputy Chair, National Standing Committee for Research, RACGP

Financial Disclosures/Conflicts of Interest

Not stated

Guideline Status

This is the current release of the guideline.

Guideline Availability

Electronic copies: Available in Portable Document Format (PDF) from the [Royal Australian College of General Practitioners \(RACGP\) Web site](#) .

Availability of Companion Documents

The following is available:

Putting prevention into practice (green book). East Melbourne (Australia): Royal Australian College of General Practitioners; 2006. 104 p.
Electronic copies: Available in PDF from the [Royal Australian College of General Practitioners \(RACGP\) Web site](#)

Patient Resources

None available

NGC Status

This NGC summary was completed by ECRI Institute on May 31, 2013.

Copyright Statement

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

Disclaimer

NGC Disclaimer

The National Guideline Clearinghouse^{â„¢} (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion-criteria.aspx>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.